GrafixPL PRIME Evaluation Case Study
| Status: | Recruiting |
|---|---|
| Conditions: | Podiatry, Diabetes |
| Therapuetic Areas: | Endocrinology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 1/9/2019 |
| Start Date: | November 20, 2018 |
| End Date: | May 2020 |
| Contact: | Tara Kristof |
| Email: | Tara.Kristof@UTSouthwestern.edu |
| Phone: | 214-648-9007 |
The investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40)
that receive optimal treatment including serial wound debridement and off-loading with total
contact casts or a boot and GrafixPL PRIME. In addition, the investigators will collect data
on other potential confounding factors that could affect healing such as medications,
tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity.
Wound healing, including wound size and adverse events will be evaluated. The objective of
this study is to understand the use of this product to evaluate wound healing in 40 patients.
that receive optimal treatment including serial wound debridement and off-loading with total
contact casts or a boot and GrafixPL PRIME. In addition, the investigators will collect data
on other potential confounding factors that could affect healing such as medications,
tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity.
Wound healing, including wound size and adverse events will be evaluated. The objective of
this study is to understand the use of this product to evaluate wound healing in 40 patients.
Screening and Enrollment:
- Review and sign the Informed Consent and HIPAA Authorization
- Review the inclusion and exclusion criteria
If the subject qualifies for the study, they will participate in the following procedures
(weekly visits, +/-4 days):
Visit 0:
- Demographics (such as age, gender, race or ethnicity)
- Medical/Surgical and Social History, Current Antibiotics.
- Laboratory Results
- Vascular - ABI
- Neurological evaluation - Monofilament and VPT
- Vitals - Sitting blood pressure and Pulse rate, Height/Weight, and BMI
- Wound debridement
- eKare - Wound imaging measurement
- Application of GrafixPL PRIME
- Current Antibiotics
- Offloading
- Adverse Events
- Source documentation
Visits 1 - 11:
- Wound debridement
- eKare - Wound imaging measurement
- Application of GrafixPL PRIME
- Current Antibiotics
- Offloading
- Adverse Events
- Source documentation
Visit 12/End of Study (EOS) Visit:
- Wound debridement
- eKare - Wound imaging measurement
- Current Antibiotics
- Offloading
- Adverse Events
- Source documentation (End of Study will occur on the date the subject is healed)
- Review and sign the Informed Consent and HIPAA Authorization
- Review the inclusion and exclusion criteria
If the subject qualifies for the study, they will participate in the following procedures
(weekly visits, +/-4 days):
Visit 0:
- Demographics (such as age, gender, race or ethnicity)
- Medical/Surgical and Social History, Current Antibiotics.
- Laboratory Results
- Vascular - ABI
- Neurological evaluation - Monofilament and VPT
- Vitals - Sitting blood pressure and Pulse rate, Height/Weight, and BMI
- Wound debridement
- eKare - Wound imaging measurement
- Application of GrafixPL PRIME
- Current Antibiotics
- Offloading
- Adverse Events
- Source documentation
Visits 1 - 11:
- Wound debridement
- eKare - Wound imaging measurement
- Application of GrafixPL PRIME
- Current Antibiotics
- Offloading
- Adverse Events
- Source documentation
Visit 12/End of Study (EOS) Visit:
- Wound debridement
- eKare - Wound imaging measurement
- Current Antibiotics
- Offloading
- Adverse Events
- Source documentation (End of Study will occur on the date the subject is healed)
Inclusion Criteria:
- Able to provide informed consent
- 18-90 years of age
- Chronic foot ulceration below the ankle - persistent for 30 days or longer
- Ankle Brachial Index (ABI) >0.5 (Bedside ABI is acceptable for screening purposes as
the formal imaging ABI may not be resulted prior to surgery)
Exclusion Criteria:
- Unable to provide informed consent
- <18 or >90 years of age
- History of poor compliance with follow-up visits
- Gangrene
- Untreated Osteomyelitis
- Widespread malignancy
- Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines
- Currently Pregnant or planning pregnancy during the course of intended participation
in the study
- Is nursing or actively lactating
We found this trial at
1
site
Click here to add this to my saved trials
